Small-molecule irreversible tyrosine kinase inhibitors as high potent agents have led to improvements in disease-free and overall survival in patients with HER2-amplified cancer. The approved ...

A novel inhibitor-loaded bilayer hybrid system based on the LDH inner layer and MOF outer layer is designed on an aluminum alloy 2A12 surface to improve corrosion performance. The hybrid film system ...

Afimetoran (BMS 986256) is a potent, selective, and orally bioavailable inhibitor of TLR7/8 currently in clinical development for immune mediated diseases. Previously, we observed that afimetoran ...

Panelists discuss potential changes to clinical pathways for Bruton tyrosine kinase (BTK) inhibitor therapies as a result of the Inflation Reduction Act (IRA), focusing on how shifting costs and ...

References: Ferrer receives FDA Fast Track designation for FNP-223 in progressive supranuclear palsy (PSP). News release. Ferrer. June 17, 2025.

After the SGLT2 inhibitors were shown to benefit patients with type 2 diabetes, reducing cardiovascular events, including hospitalization for heart failure, the next natural research question, ...

Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib ...

Pirtobrutinib, a noncovalent, Bruton tyrosine kinase inhibitor (BTKi), has shown clinical efficacy and a favorable safety profile. BRUIN CLL-321 was an open-label, randomized phase III study conducted ...

About Seyltx: Seyltx (www.seyltx.com) is a clinical stage biotherapeutics company focused on developing innovative therapies to treat chronic cough and other neuronal hypersensitivity indications.Its ...

An SGLT2 inhibitor helped improve metabolic dysfunction-associated steatohepatitis (MASH) in people with or without type 2 diabetes, a randomized trial in China found.

Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only covalent Werner helicase (WRN) inhibitor to have made it into the clinic.. Vividion and Roche have ...